Ion Beam Applications SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: BE0003766806
EUR
11.22
-1.91 (-14.55%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Ion Beam Applications SA stock-summary
stock-summary
Ion Beam Applications SA
Pharmaceuticals & Biotechnology
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
Company Coordinates stock-summary
Company Details
Chemin du Cyclotron 3 , LOUVAIN-LA-NEUVE None : 1348
stock-summary
Tel: 32 10 47581132 10 475890
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Pierre Mottet
Chairman of the Board, Representing Saint-Denis SA
Mr. Olivier Legrain
Chief Executive Officer, Managing Director, Inside Director
Mr. Yves Jongen
Chief Research Officer, Managing Director, Inside Director, representing Technofutur SA
Ms. Christine Dubus
Non-Executive Director
Mr. Richard Hausmann
Non-Executive Director
Ms. Hedvig Hricak
Independent Director
Mr. Marcel Miller
Independent Director, Representing Consultance Marcel Miller SCS
Ms. Sybille Van Den Hove
Independent Director, Representing Bridging for Sustainability SPRL
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
59 Million
(Quarterly Results - Sep 2012)
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 334 Million ()

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.03

stock-summary
Return on Equity

14.29%

stock-summary
Price to Book

2.81